Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30% ...

Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million, bringing together two companies working on central nervous system therapies that have suffered ...

About a month ago, I predicted that button locks would be one of the biggest trends in the EDC knife industry this year. While I’m no Nostradamus, I may have been onto something. With the release of ...

In the Iowa House, Bloomingdale chairs the State Government Committee. She also serves on the Local Government and Ways and ...

An analysis by Investigate Midwest shows that progress in removing river segments from the impaired waters list has been ...

Lindsey Vonn's Olympic crash has renewed pressure to rethink ski bindings, one of the oldest pieces of equipment in the sport ...

Sage is over the hump in its transition to a primary cloud-focused software company. which means operating margins should rise going forward as the benefits of scale kick in.